CHICAGO (AP) — Seiya Suzuki hit a three-run homer, and the Chicago Cubs stopped Boston's 10-game win streak with a 4-1 victory over the Red Sox on Friday.
Colin Rea pitched five effective innings for Chicago in the majors' first game after the All-Star break. Working around a season-high four walks, the right-hander allowed one run and four hits in his fourth consecutive win.
Click to Gallery
Boston Red Sox starter Lucas Giolito throws during the first inning of a baseball game against the Chicago Cubs, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs starter Colin Rea delivers during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs' Seiya Suzuki (27) celebrates at home plate with teammate Michael Busch, right, after hitting a three-run home run during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs' Seiya Suzuki celebrates while rounding the bases after hitting a three-run home run during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Boston had won 12 of 13 to surge into contention in the rugged AL East. But Lucas Giolito got off to shaky start and the Red Sox left eight runners on base in the opener of a challenging six-game trip.
Pitching for the first time since July 9, Giolito (6-2) walked his first two batters of the game. Suzuki then drove a four-seam fastball deep to center for his 26th homer, delighting the crowd of 41,011 on a picturesque afternoon at Wrigley Field.
Nico Hoerner tacked on an RBI single for the NL Central leaders in the sixth.
Giolito was charged with four runs and five hits in 5 1/3 innings in his first loss since May 6. The right-hander went 5-0 with a sparkling 0.70 ERA in his previous six starts.
Boston scored its only run on Roman Anthony's two-out RBI double in the third. Anthony's hit put runners on second and third, but Rea (8-3) escaped the jam by striking out Carlos Narváez.
Brad Keller pitched a perfect eighth for Chicago before Daniel Palencia handled the ninth for his 13th save in 14 opportunities.
Boston had a chance to rally in the fifth, but Abraham Toro committed a costly mistake. With two runners on and no outs, Toro was doubled off second on Alex Bregman's liner to center.
The Cubs improved to 40-7 when they score first.
Brayan Bello (6-3, 3.14 ERA) pitches for Boston on Saturday, and left-hander Shota Imanaga (6-3, 2.65) takes the mound for Chicago.
AP MLB: https://apnews.com/hub/mlb
Boston Red Sox starter Lucas Giolito throws during the first inning of a baseball game against the Chicago Cubs, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs starter Colin Rea delivers during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs' Seiya Suzuki (27) celebrates at home plate with teammate Michael Busch, right, after hitting a three-run home run during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
Chicago Cubs' Seiya Suzuki celebrates while rounding the bases after hitting a three-run home run during the first inning of a baseball game against the Boston Red Sox, Friday, July 18, 2025, in Chicago. (AP Photo/Paul Beaty)
NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/
The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.
“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”
The deployment of Oracle Argus will enable QPS to:
As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.
###
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.
ABOUT ORACLE ARGUS
Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
